Core Depressive Symptoms In Depressed Cancer OutpatientsB by Pasquini, Massimo et al.
178  Clinical Practice & Epidemiology in Mental Health, 2011, 7, 178-181   
 
  1745-0179/11  2011 Bentham Open 
Open Access 
Core Depressive Symptoms In Depressed Cancer Outpatients 
Pasquini Massimo*, Berardelli Isabella, Cabra Ambra, Maraone Annalisa, Matteucci Gabriella, and 
Biondi Massimo 
Department of Neurology and Psychiatry, Psycho-oncology Unit, Rome, Italy 
Abstract: Objective: This study aimed to estimate the prevalence of core depressive symptoms among cancer outpatients 
diagnosed with depressive or adjustment disorders with depressed mood. We also aimed to detect potential differences be-
tween patient self-assessment and psychiatrist evaluation in classifying the severity of depression.  
Methods: Fifty-two outpatients diagnosed with solid tumor malignancy and depressive or adjustment disorder with de-
pressed mood were assessed using the Hamilton Depression Rating Scale (HAMD-17) (and its shortened version the 
HAMD-7) and the Zung Self-Rating Depression Scale (ZSDS) (and its shortened version BZSDS).  
Results: Based on HAMD-7 results, the prevalence of moderate depression was low (7.7%); using the BZSDS moderate 
depression was absent. Mild depression was identified in 82.3% and 73% of our subjects using the HAMD-7 and the 
BZSDS, respectively. The strength of agreement between psychiatrist and patients’ self-evaluation for mild depression 
was “slight”, employing the original and the abbreviated versions of both scales.  
Conclusion: Our findings suggest that the prevalence of core depressive symptoms is very low in cancer patients diag-
nosed with depressive disorder. The lack of a strong agreement between psychiatrist and patient in classifying the severity 
of depression highlights the importance of factors such as well-being and functional status among depressed cancer pa-
tients in their self assessment of depression. 
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INTRODUCTION 
The reported prevalence of major depression among can-
cer patients is highly variable [1]; this variation can be at-
tributed to differences in study populations, procedures, in-
struments, observers, and patient variables. In addition, 
nosological classification is unhelpful to clinicians and re-
searchers in diagnosing depressive disorders in subjects with 
medical illness. Assessing depression symptoms in cancer 
patients often involves differentiating between a depressive 
disorder and an adjustment disorder with depressive mood. 
Adjustment disorder with depressive mood is linked to a 
specific triggering occurence and places itself in a transi-
tional zone on the continuum of distress between normative 
adaptation and a psychiatric disorder. As a consequence, 
adjustment disorders are frequently addressed in depressed 
cancer patients as an “afterthought” [2]. Furthermore, an 
epidemiological study failed to distinguish between adjust-
ment disorders and depressive episode [3]. In order to evalu-
ate the severity of depression in cancer patients it is neces-
sary to adopt an approach that discriminate the somatic 
symptoms of cancer from those due to treatment from the 
criteria of DSM-IV for major depression. The proposed “ex-
clusive approach” [4] to the diagnosis of major depression in 
this population may increase the specificity of the diagnosis.  
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This approach excludes somatic symptoms of depression, 
such as fatigue, weight loss, loss of appetite or sleep disrup-
tion from the nuclear depressive symptoms. The presence of 
core depressive symptoms, that comprise excessive or inap-
propriate guilt, sense of failure, dissatisfaction and self-
dislike, among cancer patients has been previously investi-
gated [5]. In spite of the crucial importance of other symp-
toms in depressed cancer patients assessing specifically typi-
cal depressive symptoms among these subjects might im-
prove clinical management.  
Moreover, apart from physicians’ judgment, understand-
ing patients’ concerns and appraisal of their depressive con-
ditions is an essential issue in assessing depression. This 
aspect is of particular importance in psycho-oncology, when 
the clinical situations are equivocal and the evidence-based 
decision-making process become difficult. 
The main goal of the present study was to assess the 
presence of core depressive symptoms among cancer outpa-
tients previously diagnosed with depressive or adjustment 
disorders with depressed mood. An additional aim was to 
detect potential differences between self-perceived mental 
status and the psychiatrist assessment.  
METHODS  
Design 
This was an observational study carried out at the Psy-
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chiatry of the SAPIENZA University of Rome, between Feb-
ruary 2009 and February 2010.  
Patients 
One rater (MP) assessed outpatients consecutively re-
ferred by two different oncology divisions. Inclusion criteria 
were: age >18 years, a diagnosis of cancer within the previ-
ous five years, and a current diagnosis of depressive disorder 
(major depressive disorders and dysthymia) or adjustment 
disorders with depressed mood according to the DSM-IV 
criteria. Exclusion criteria were: presence of a neurological 
disorder or cerebral metastases, presence of comorbid psy-
chiatric diagnosis, bipolar disorder, or exposure to psycho-
tropic drugs in the preceding month. Approval from the 
Hospital Ethical Committees and written informed consent 
from participants were obtained. 
Assessment 
Study assessments were done at the Psycho-oncology 
Unit during the first visit. All patients were given the self-
administered Zung Self Depressive Scale in the waiting 
room. All patients were diagnosed according to DSM-IV 
criteria and blindly assessed by the principal investigator 
(M.P.), who was the only rater in this study. The HAMD-17 
was used to assess the severity of depression. The brief ver-
sions, HAMD-7 and BZSDS [6, 7], were employed to detect 
melancholic symptoms. The HAMD-7 and the BZSDS both 
focus on the core depressive symptoms of depression, mini-
mizing the anxiety or somatic items. The BZSDS is a 11-
version of the well-known ZSDS that limits the somatic 
items. Psychometrics properties were previously studied for 
both instruments [6, 7]. In order to assess the severity of core 
depressive symptoms we employed the suggested cut-off 
scores for the HAMD-7 (0-3 Normal, 4-12: mild, 13-20: 
moderate, >20: severe) and for the BZSDS (11-21 Normal, 
22-32: mild, 33-38: moderate, 39-44: severe). We also used 
the suggested cut off scores for the HAMD-17 (<7: normal, 
8-17: mild, 18-24: moderate, 25: severe) and for the ZSDS 
(20-39: normal, 40-47: mild, 48-55: moderate, 56-80: se-
vere). 
Statistical Analysis 
We described the frequency distribution of all variables 
of interest, and estimated their prevalence and 95% confi-
dence intervals. Scores on the HAMD-7 and the BZSDS 
were classified according to the above mentioned severity 
criteria. Specificity, sensitivity, positive predictive value, and 
negative predictive value for ZSDS and BZSDS were calcu-
lated. Degree of agreement between patients and psychiatrist 
were assessed by Cohen’s kappa. SPSS for Windows, ver-
sion 13.0 was used for all analyses. 
Results 
Of the 63 patients invited to participate, 52 (82%) were 
enrolled in the study; 11 were not eligible because of their 
psychiatric diagnoses. Socio-demographic and clinical char-
acteristics are shown in Table 1. The majority of the subjects 
were classified as suffering from an adjustment disorder with 
depressed mood (63.5%); major depressive disorder and 
dysthymia were diagnosed in 28.9% and 7.6% of patients, 
respectively (Table 2). Severe depressive symptoms were 
absent according to HAMD-7, HAMD-17 and BZSDS while 
using the ZSDS, 38.5% of patients were classified as having 
severe depression. Point estimates of core symptoms preva-
lences and 95% confidence intervals limits are shown in   
Table 3. 
Table 1. Patient Characteristics 
N 52 
AGE, YEARS, MEAN (SD)  54.63±11.3 
GENDER, M/F 
M 14 (26.9%) 
F 38(73.1%) 
MARITAL STATUS, 
N (%) 
Single 5 (9.6%) 
Married 35 (67.3%) 
Separate/Divorced 6 (11.5%) 
Widowed 6 (11.5%) 
EDUCATIONAL STATUS,  
N (%) 
Primary School 8 (15,4%). 
Middle School 16 (30.8%) 
Graduate 19 (36.5%) 
Degree   9 (17.3%) 
OCCUPATION, 
N (%) 
  Retired 15 (28.8%) 
Employee 16(30.8%) 
Privately employed 7 (13.5%) 
Not working 3 (5.8%) 
Housewife 8 (15.4%) 
Other 3 (5.8%) 
TIME SINCE CANCER  
DIAGNOSIS (MONTHS)  N (%) 
0-3 MONTHS   10 (19.2%) 
3-6 MONTHS   7 (13.5%) 
6-12 MONTHS   10 (19.2%) 
12-24 MONTHS   8 (15.4%) 
MORE THAN 24 MONTHS   17 (32.7%) 
STAGE N  (%) 
0 3  (5.8%) 
I 7  (13.5%) 
II 12  (23.1%) 
III 13  (25.0%) 
IV 17  (32.7%) 
CANCER LOCATION  N(%) 
BREAST 26  (50.0%) 
PROSTATE 4  (7.7%) 
GASTROINTESTINAL 
TRACT  7 (13.5%) 
STOMACH 1  (1.9%) 
LUNG 5  (9.6%) 
OVARY 3  (5.8%) 
OTHER   6 (11.5%) 
TREATMENT TYPE  Y/N (%) 
SURGERY 
Yes 46 (88.5%) 
No 6 (11.5%) 
CHEMOTHERAPY 
Yes 37 (71.2%) 
No 15 (28.8%) 
RADIATION 
Yes 20 (38.5%) 
No 32 (61.5%) 180    Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7  Massimo et al. 
Results According to the HAMD-7 and BZSDS 
Mean scores observed for HAMD-7 and BZSDS were 
7.06±3.4 and 23±4.5, respectively, indicating mild depres-
sion (Table 2). Out of 52 study subjects, only 7.7% were 
classified as moderately depressed according to the HAMD-
7, whereas no patient we found to be moderately depressed 
according to the BZSDS. Using the HAMD-7, 82.3% were 
classified with mild depression; 73% were found to have 
mild depression according to the BZSDS. Assuming the 
HAMD-7 as the gold standard, sensitivity, specificity, posi-
tive predictive value, and negative predictive value of the 
BZSDS in classifying mild depression were 76.6%, 44%, 
86.8%, and 28.5%, respectively. The strength of agreement 
between psychiatrist (HAMD-7) and patients’ (BZSDZ) 
evaluation for the presence of mild depression was “slight” 
(71% agreement; kappa=0.173 with 95% CI 0.567 to 0.824) 
[8]. 
Results According to the HAMD-17 and ZSDS 
Mean scores observed for HAMD-17 and ZSDS were 
13±5.92 and 51.7±8.91, respectively. According to the 
HAMD-17 the prevalence of moderate depression was 
13.5%; with the ZSDS the prevalence of moderate depres-
sion was 34.6%. Using the HAMD-17, 75% of patients were 
classified as having mild depression; ZSDS classified 11.5% 
of patients as having mild depression. Twenty patients 
(38.5%) were classified as severe depressed according to the 
ZSDS. According to HAM-17, 11.5% of patients obtained a 
score < 7. Assuming the HAMD-17 as the gold standard, 
sensitivity, specificity, positive predictive value, and nega-
tive predictive value of the ZSDS in classifying mild depres-
sion were 12.8%, 92.3%, 83.3%, and 26.1%, respectively. 
The strength of agreement between psychiatrist (HAMD-17) 
and patients (ZSDS) evaluation for the presence of mild de-
pression was “slight” (32% agreement; kappa=0,028 with 
95% CI 0.20 to 0.47). 
DISCUSSION 
In our sample of depressed cancer patients, core depres-
sive symptoms were present in a minority of them. Feelings 
of guilt and suicide ideation were present respectively in 
23% and 9.6% of participants. Whereas interest, pleasure and 
level of activities was detected in 92% of patients. This latter 
finding might be overestimated because physical or mental 
fatigue are often related to cancer therapies. The prevalence 
of moderate depression was low (7.7%) for the HAMD-7, 
while no patient was found to have moderate depression ac-
cording to the BZSDS. Mild depression was identified using 
HAMD-7 and BZSDS in 82.3% and 73% of participants, 
respectively. As expected, employing the HAMD-17 and the 
ZSDS detected a higher rate of moderate depression, because 
these scales include somatic symptoms, which could also be 
attributable to cancer or medications. These results stress the 
importance of using appropriate tools for the assessment of 
core depressive symptoms in cancer patients. From a prag-
matic point of view, however, the severity of depression, or 
the presence of nuclear depressive symptoms, should not be 
considered a unique indicator for intervention, as we know 
that antidepressants and psychotherapies for sub-threshold 
depression, anxiety, and other conditions such as hot flashes 
or pain in cancer patients are appropriate and effective. Nev-
ertheless, the assessment of depression as such might im-
prove therapeutic decision-making, in terms of medication 
dosage and length of treatment. The high rate of mild de-
pression found in our study is attributable to the high preva-
lence of adjustment disorders with depressed mood (63%) 
among our study subjects, since, as already reported, the 
distribution of depression severity does not differ between 
adjustment disorders and depressive disorders [3]. Since the 
BZSDS detected no cases of moderate depression, we re-
stricted our considerations to mild depression. Given the 
high prevalence of mild depression in our sample, the posi-
tive predicting value of the BZSDS is high (86.8%), and the 
negative predictive value is quite low (28.5%). This observa-
tion suggests that, in similar settings, excluding the presence 
of mild depression on the basis of BZSDS alone leads to a 
false positive rate as high as 71.5%. Another purpose of our 
study was to assess the degree of agreement between psy-
chiatrist and patients concerning the severity of depression. 
Overall, the results of this study suggest a “slight” agree-
ment, which in our opinion is unsatisfactory, for both the 
shortened versions and the original versions of the scales. 
The latter, which includes somatic symptoms, is an applica-
tion of the “inclusive approach” for discriminating somatic 
symptoms of cancer [4]. On this basis we speculate that pa-
tients’ perspective of their own depressive status incorpo-
rates features other than depressive symptoms, such as the 
impairment of their general sense of well-being or functional 
status [9, 10] These factors might explain the lack of a strong 
agreement between patients and psychiatrist. This observa-
tion is useful in that it reflects actual clinical practice. This 
study have several limitations. The main limitation of our 
Table 2. Psychiatric Diagnoses and Scores on Measures for 
Depression Severity 
ADJUSTMENT DISORDERS WITH 
DEPRESSED MOOD 
33 (63.5%) 
DYSTHYMIA  4 (7.6%) 
MAJOR DEPRESSIVE DISORDER  15 (28.9%) 
  Mean (S.D.) 
HAM-D 17  12.9±6 
HAM-D 7  7.06±3.2 
ZSDS  51.1±9 
BZSDS  23±4.5 
Table 3. Prevalence rate of Symptoms According to the 
HAMD-7 
 Prevalence  Confidence  Intervals 
Depressive Mood  96%  0.87-0.98 
Feelings of Guilt  23%  0.13-0.36 
Work and activities  92%  0.81-0.96 
Suicide 9.6%  0.42-0.20 
Psychological anxiety  94%  0.84-0.97 
Somatic Anxiety  50%  0.36-0.62 
Somatic Symptoms  52%  0.38-0.64 Core Depressive Symptoms In Depressed Cancer Outpatients  Clinical Practice & Epidemiology in Mental Health, 2011, Volume 7    181 
study is sample size; a larger sample would improve the pre-
cision of the estimates. In addition, accuracy of diagnosis 
may be decreased due to the choice to employ the DSM-IV 
criteria rather than the SCID-I. Another limitation is the ex-
ternal validity of our results, since the overrepresentation of 
breast cancer in our sample limits the generalizability of our 
inferences. 
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